Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

Hadassah Medical Center - Gene Therapy: Peled Amnon


Last updated December 2021 - Gene Therapy

List of Publications

(1) Bockorny B, Macarulla T, Semenisty V, Borazanci E, Feliu J, Ponz-Sarvise M, et al. Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: The COMBAT/ KEYNOTE-202 trial. Clin Cancer Res 2021;27(18):5020-5027.

(2) Shriki A, Lanton T, Sonnenblick A, Levkovitch-Siany O, Eidelshtein D, Abramovitch R, et al. Multiple roles of il6 in hepatic injury, steatosis, and senescence aggregate to suppress tumorigenesis. Cancer Res 2021;81(18):4766-4777.

(3) Borthakur G, Ofran Y, Tallman MS, Foran J, Uy GL, DiPersio JF, et al. BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. Cancer 2021;127(8):1246-1259.

(4) Becker-Herman S, Rozenberg M, Hillel-Karniel C, Gil-Yarom N, Kramer M, Barak A, et al. CD74 is a regulator of hematopoietic stem cell maintenance. PloS Biol 2021;19(3).

(5) Beider K, Rosenberg E, Dimenshtein-Voevoda V, Sirovsky Y, Vladimirsky J, Magen H, et al. Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response. J Hematol Oncol 2020;13(1).

(6) Levy-Barazany H, Shachnai-Pinkas L, Rodionov G, Saar A, Rosenzwaig M, Gez L, et al. Brief ex vivo Fas-ligand incubation attenuates GvHD without compromising stem cell graft performance. Bone Marrow Transplant 2020;55(7):1305-1316.

(7) Bockorny B, Semenisty V, Macarulla T, Borazanci E, Wolpin BM, Stemmer SM, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med 2020;26(6):878-885.

(8) Beider K, Bitner H, Voevoda-Dimenshtein V, Rosenberg E, Sirovsky Y, Magen H, et al. The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators. Biochem Pharmacol 2019;168:412-428.

(9) Hagbi-Levi S, Abraham M, Tiosano L, Rinsky B, Grunin M, Eizenberg O, et al. Promiscuous Chemokine Antagonist (BKT130) Suppresses Laser-Induced Choroidal Neovascularization by Inhibition of Monocyte Recruitment. J Immunol Res 2019;2019.

(10) Peled A, Klein S, Beider K, Burger JA, Abraham M. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies. Cytokine 2018;109:11-16.

(11) Ella E, Harel Y, Abraham M, Wald H, Benny O, Karsch-Bluman A, et al. Matrix metalloproteinase 12 promotes tumor propagation in the lung. J Thorac Cardiovasc Surg 2018;155(5):2164-2175.e1.

(12) Klein S, Abraham M, Bulvik B, Dery E, Weiss ID, Barashi N, et al. CXCR4 promotes neuroblastoma growth and therapeutic resistance through miR-15a/ 16-1–mediated ERK and BCL2/Cyclin D1 pathways. Cancer Res 2018;78(6):1471-1483.

(13) Peled A, Nagler A. NK cell destiny after haploSCT with PT-Cy. Blood 2018;131(2):161-162.

(14) Abraham M, Wald H, Vaizel-Ohayon D, Grabovsky V, Oren Z, Karni A, et al. Development of novel promiscuous anti-chemokine peptibodies for treating autoimmunity and inflammation. Front Immunol 2017;8(NOV).

(15) Abraham M, Pereg Y, Bulvik B, Klein S, Mishalian I, Wald H, et al. Single dose of the CXCR4 antagonist BL-8040 induces rapid mobilization for the collection of human CD34 + cells in healthy volunteers. Clin Cancer Res 2017;23(22):6790-6801.

(16) Abraham M, Klein S, Bulvik B, Wald H, Weiss ID, Olam D, et al. The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression. Leukemia 2017;31(11):2336-2346.

(17) Abraham M, Karni A, Mausner-Fainberg K, Weiss ID, Peled A. Natural and induced immunization against CCL20 ameliorate experimental autoimmune encephalitis and may confer protection against multiple sclerosis. Clin Immunol 2017;183:316-324.

(18) Lanton T, Shriki A, Nechemia-Arbely Y, Abramovitch R, Levkovitch O, Adar R, et al. Interleukin 6–dependent genomic instability heralds accelerated carcinogenesis following liver regeneration on a background of chronic hepatitis. Hepatology 2017;65(5):1600-1611.

(19) Beider K, Rosenberg E, Bitner H, Shimoni A, Leiba M, Koren-Michowitz M, et al. The sphingosine-1-phosphate modulator FTY720 targets multiple myeloma via the CXCR4/CXCL12 pathway. Clin Cancer Res 2017;23(7):1733-1747.

(20) Hagbi-Levi S, Grunin M, Jaouni T, Tiosano L, Rinsky B, Elbaz-Hayoun S, et al. Proangiogenic characteristics of activated macrophages from patients with age-related macular degeneration. Neurobiol Aging 2017;51:71-82.

(21) Randhawa S, Cho BS, Ghosh D, Sivina M, Koehrer S, Müschen M, et al. Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia. Br J Haematol 2016;174(3):425-436.

(22) Matza D, Badou A, Klemic KG, Stein J, Govindarajulu U, Nadler MJ, et al. T cell receptor mediated calcium entry requires alternatively spliced Cav1.1 channels. PLoS ONE 2016;11(1).

(23) Weiss ID, Ella E, Dominsky O, Smith Y, Abraham M, Wald H, et al. In the hunt for therapeutic targets: Mimicking the growth, metastasis, and stromal associations of early-stage lung cancer using a novel orthotopic animal model. J Thorac Oncol 2015;10(1):46-58.

(24) Horwitz ME, Chao NJ, Rizzieri DA, Long GD, Sullivan KM, Gasparetto C, et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Invest 2014;124(7):3121-3128.

(25) Peled A, Abraham M, Avivi I, Rowe JM, Beider K, Wald H, et al. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma. Clin Cancer Res 2014;20(2):469-479.

(26) Beider K, Bitner H, Leiba M, Gutwein O, Koren-Michowitz M, Ostrovsky O, et al. Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. Oncotarget 2014;5(22):11283-11296.

(27) Beider K, Darash-Yahana M, Blaier O, Koren-Michowitz M, Abraham M, Wald H, et al. Combination of imatinib with CXCR4 Antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo. Mol Cancer Ther 2014;13(5):1155-1169.

(28) Abraham M, Weiss ID, Wald H, Wald O, Nagler A, Beider K, et al. Sequential administration of the high affinity CXCR4 antagonist BKT140 promotes megakaryopoiesis and platelet production. Br J Haematol 2013;163(2):248-259.

(29) Peled A, Tavor S. Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Theranostics 2013;3(1):34-39.

(30) Barashi N, Weiss ID, Wald O, Wald H, Beider K, Abraham M, et al. Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice. Hepatology 2013;58(3):1021-1030.

(31) Beider K, Ribakovsky E, Abraham M, Wald H, Weiss L, Rosenberg E, et al. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140. Clin Cancer Res 2013;19(13):3495-3507.

(32) Potikha T, Stoyanov E, Pappo O, Frolov A, Mizrahi L, Olam D, et al. Interstrain differences in chronic hepatitis and tumor development in a murine model of inflammation-mediated hepatocarcinogenesis. Hepatology 2013;58(1):192-204.

(33) Eldor R, Abel R, Sever D, Sadoun G, Peled A, Sionov R, et al. Inhibition of Nuclear Factor-κB Activation in Pancreatic β-Cells Has a Protective Effect on Allogeneic Pancreatic Islet Graft Survival. PLoS ONE 2013;8(2).

(34) Peled A. Microenvironmental mediators as therapeutic targets in malignancy. The Inflammatory Milieu of Tumors: Cytokines and Chemokines that Affect Tumor Growth and Metastasis; 2012. p. 155-167.

(35) Fahham D, Weiss ID, Abraham M, Beider K, Hanna W, Shlomai Z, et al. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non–small cell lung cancer. J Thorac Cardiovasc Surg 2012;144(5):1167-1175.e1.

(36) Grunin M, Burstyn-Cohen T, Hagbi-Levi S, Peled A, Chowers I. Chemokine receptor expression in peripheral blood monocytes from patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2012;53(9):5292-5300.

(37) Peled A, Wald O, Burger J. Development of novel CXCR4-based therapeutics. Expert Opin Invest Drugs 2012;21(3):341-353.

(38) Jacobson O, Weiss ID, Szajek LP, Niu G, Ma Y, Kiesewetter DO, et al. Improvement of CXCR4 tracer specificity for PET imaging. J Control Release 2012;157(2):216-223.

(39) Peled A, Nagler A. Role of the CXCR4/CXCL12 axis in hematopoietic stem cell trafficking. Novel Developments in Stem Cell Mobilization: Focus on CXCR4; 2012. p. 71-85.

(40) Josefsberg Ben-Yehoshua L, Beider K, Shimoni A, Ostrovsky O, Samookh M, Peled A, et al. Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell death. PLoS ONE 2012;7(4).

(41) Peled T, Shoham H, Aschengrau D, Yackoubov D, Frei G, Rosenheimer G N, et al. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment. Exp Hematol 2012;40(4):342-355.e1.

(42) Mishalian I, Ordan M, Peled A, Maly A, Eichenbaum MB, Ravins M, et al. Recruited macrophages control dissemination of group A Streptococcus from infected soft tissues. J Immunol 2011;187(11):6022-6031.

(43) Kirshberg S, Izhar U, Amir G, Demma J, Vernea F, Beider K, et al. Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. PLoS ONE 2011;6(9).

(44) Wald O, Izhar U, Amir G, Kirshberg S, Shlomai Z, Zamir G, et al. Interaction between neoplastic cells and cancer-associated fibroblasts through the CXCL12/CXCR4 axis: Role in non-small cell lung cancer tumor proliferation. J Thorac Cardiovasc Surg 2011;141(6):1503-1512.

(45) Weiss ID, Shoham H, Wald O, Wald H, Beider K, Abraham M, et al. Ccr5 deficiency regulates the proliferation and trafficking of natural killer cells under physiological conditions. Cytokine 2011;54(3):249-257.

(46) Burger JA, Stewart DJ, Wald O, Peled A. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev Anticancer Ther 2011;11(4):621-630.

(47) Beider K, Begin M, Abraham M, Wald H, Weiss ID, Wald O, et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol 2011;39(3):282-292.

(48) Weiss ID, Wald O, Wald H, Beider K, Abraham M, Galun E, et al. IFN-γ treatment at early stages of influenza virus infection protects mice from death in a NK cell-dependent manner. J Interferon Cytokine Res 2010;30(6):439-449.

(49) Rudich N, Zamir G, Pappo O, Shlomai Z, Faroja M, Weiss ID, et al. Focal liver necrosis appears early after partial hepatectomy and is dependent on T cells and antigen delivery from the gut. Liver Int 2009;29(8):1273-1284.

(50) Darash-Yahana M, Gillespie JW, Hewitt SM, Chen Y-K, Maeda S, Stein I, et al. The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. PLoS ONE 2009;4(8).

(51) Hayun M, Saida H, Albeck M, Peled A, Haran-Ghera N, Sredni B. Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model. Exp Hematol 2009;37(5):593-603.

(52) Beider K, Abraham M, Begin M, Wald H, Weiss ID, Wald O, et al. Interaction between CXCR4 and CCL20 pathways regulates tumor growth. PLoS ONE 2009;4(4).

(53) Abraham M, Beider K, Wald H, Weiss ID, Zipori D, Galun E, et al. The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation. Leukemia 2009;23(8):1378-1388.

(54) Burger JA, Peled A. CXCR4 antagonists: Targeting the microenvironment in leukemia and other cancers. Leukemia 2009;23(1):43-52.

(55) Lapidot A, Peled A, Berchanski A, Pal B, Kollet O, Lapidot T, et al. NeoR6 inhibits HIV-1-CXCR4 interaction without affecting CXCL12 chemotaxis activity. Biochim Biophys Acta Gen Subj 2008;1780(6):914-920.

(56) Beider K, Abraham M, Peled A. Chemokines and chemokine receptors in stem cell circulation. Front Biosci 2008;13(17):6820-6833.

(57) Abraham M, Biyder K, Begin M, Wald H, Weiss ID, Galun E, et al. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4f-benzoyl-TN14003. Stem Cells 2007;25(9):2158-2166.

(58) Wald O, Weiss ID, Galun E, Peled A. Chemokines in hepatitis C virus infection: Pathogenesis, prognosis and therapeutics. Cytokine 2007;39(1):50-62.

(59) Gavish M, Peled A, Chor B. Genetic code symmetry and efficient design of GC-constrained coding sequences. Bioinformatics 2007;23(2):e57-e63.

(60) Hayun M, Naor Y, Weil M, Albeck M, Peled A, Don J, et al. The immunomodulator AS101 induces growth arrest and apoptosis in Multiple Myeloma: Association with the Akt/Survivin pathway. Biochem Pharmacol 2006;72(11):1423-1431.

(61) Wald O, Izhar U, Amir G, Avniel S, Bar-Shavit Y, Wald H, et al. CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma. J Immunol 2006;177(10):6983-6990.

(62) Hidalgo-Grass C, Mishalian I, Dan-Goor M, Belotserkovsky I, Eran Y, Nizet V, et al. A streptococcal protease that degrades CXC chemokines and impairs bacterial clearance from infected tissues. EMBO J 2006;25(19):4628-4637.

(63) Dagan-Berger M, Feniger-Barish R, Avniel S, Wald H, Galun E, Grabovsky V, et al. Role of CXCR3 carboxyl terminus and third intracellular loop in receptor-mediated migration, adhesion and internalization in response to CXCL11. Blood 2006;107(10):3821-3831.

(64) Wald O, Weiss ID, Wald H, Shoham H, Bar-Shavit Y, Beider K, et al. IFN-γ acts on T cells to induce NK cell mobilization and accumulation in target organs. J Immunol 2006;176(8):4716-4729.

(65) Eldor R, Yeffet A, Baum K, Doviner V, Amar D, Ben-Neriah Y, et al. Conditional and specific NF-κB blockade protects pancreatic beta cells from diabetogenic agents. Proc Natl Acad Sci U S A 2006;103(13):5072-5077.

(66) Avniel S, Arik Z, Maly A, Sagie A, Basst HB, Yahana MD, et al. Involvement of the CXCL12/CXCR4 pathway in the recovery of skin following burns. J Invest Dermatol 2006;126(2):468-476.

(67) Ahlenstiel G, Iwan A, Nattermann J, Bueren K, Rockstroh JK, Brackman HH, et al. Distribution and effects of polymorphic RANTES gene alleles in HIV/HCV coinfection - A prospective cross-sectional study. World J Gastroenterol 2005;11(48):7631-7638.

(68) Byk T, Kahn J, Kollet O, Petit I, Samira S, Shivtiel S, et al. Cycling G1 CD34+/CD38+ cells potentiate the motility and engraftment of quiescent G0 CD34+/CD38-/low severe combined immunodeficiency repopulating cells. Stem Cells 2005;23(4):561-574.

(69) Petit I, Goichberg P, Spiegel A, Peled A, Brodie C, Seger R, et al. Atypical PKC-ζ regulates SDF-1-mediated migration and development of human CD34+ progenitor cells. J Clin Invest 2005;115(1):168-176.

(70) Wald O, Pappo O, Ari ZB, Azzaria E, Wiess ID, Gafnovitch I, et al. The CCR5Δ32 allele is associated with reduced liver inflammation in hepatitis C virus infection. Eur J Immunogenet 2004;31(6):249-252.

(71) Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 2004;18(11):1240-1242.

(72) Franitza S, Grabovsky V, Wald O, Weiss I, Beider K, Dagan M, et al. Differential usage of VLA-4 and CXCR4 by CD3+CD56+ NKT cells and CD56+CD16+ NK cells regulates their interaction with endothelial cells. Eur J Immunol 2004;34(5):1333-1341.

(73) Spiegel A, Kollet O, Peled A, Abel L, Nagler A, Bielorai B, et al. Unique SDF-1-induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling. Blood 2004;103(8):2900-2907.

(74) Avigdor A, Goichberg P, Shivtiel S, Dar A, Peled A, Samira S, et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood 2004;103(8):2981-2989.

(75) Wald O, Pappo O, Safadi R, Dagan-Berger M, Beider K, Wald H, et al. Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur J Immunol 2004;34(4):1164-1174.

(76) Samira S, Ferrand C, Peled A, Nagler A, Tovbin Y, Ben-Hur H, et al. Tumor necrosis factor promotes human T-cell development in nonobese diabetic/severe combined immunodeficient mice. Stem Cells 2004;22(6):1085-1100.

(77) Beider K, Nagler A, Wald O, Franitza S, Dagan-Berger M, Wald H, et al. Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood 2003;102(6):1951-1958.

(78) Hanna J, Wald O, Goldman-Wohl D, Prus D, Markel G, Gazit R, et al. CXCL12 expression by invasive trophoblasts induces the specific migration of CD16- human natural killer cells. Blood 2003;102(5):1569-1577.

(79) Kollet O, Petit I, Kahn J, Samira S, Dar A, Peled A, et al. Human CD34+CXCR4- sorted cells harbor intracellular CXCR4, which can be functionally expressed and provide NOD/SCID repopulation. Blood 2002;100(8):2778-2786.

(80) Peled A, Hardan I, Trakhtenbrot L, Gur E, Magid M, Darash-Yahana M, et al. Immature leukemic CD34+CXCR4+ cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1. Stem Cells 2002;20(3):259-266.

(81) Yam D, Peled A, Shinitzky M. Suppression of tumor growth and metastasis by dietary fish oil combined with vitamins E and C and cisplatin. Cancer Chemother Pharmacol 2001;47(1):34-40.

(82) Kollet O, Spiegel A, Peled A, Petit I, Byk T, Hershkoviz R, et al. Rapid and efficient homing of human CD34+CD38-/lowCXCR4+ stem and progenitor cells to the bone marrow and spleen of NOD/SCID and NOD/SCID/B2mnull mice. Blood 2001;97(10):3283-3291.

(83) Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci U S A 2001;98(9):5181-5186.

(84) Grabovsky V, Feigelson S, Chen C, Bleijs DA, Peled A, Cinamon G, et al. Subsecond induction of α4 integrin clustering by immobilized chemokines stimulates leukocyte tethering and rolling on endothelial vascular cell adhesion molecule 1 under flow conditions. J Exp Med 2000;192(4):495-505.

(85) Gonzalo J-, Lloyd CM, Peled A, Delaney T, Coyle AJ, Gutierrez-Ramos J-. Critical involvement of the chemotactic axis CXCR4/stromal cell-derived factor-1α in the inflammatory component of allergic airway disease. J Immunol 2000;165(1):499-508.

(86) Peled A, Kollet O, Ponomaryov T, Petit I, Franitza S, Grabovsky V, et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34+ cells: Role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 2000;95(11):3289-3296.

(87) Kollet O, Peled A, Byk T, Ben-Hur H, Greiner D, Shultz L, et al. β2 microglobulin-deficient (B2m(null)) NOD/SCID mice are excellent recipients for studying human stem cell function. Blood 2000;95(10):3102-3105.

(88) Goldman Y, Peled A, Shinitzky M. Effective elimination of lung metastases induced by tumor cells treated with hydrostatic pressure and N-acetyl-L-cysteine. Cancer Res 2000;60(2):350-358.

(89) Ponomaryov T, Peled A, Petit I, Taichman RS, Habler L, Sandbank J, et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 2000;106(11):1331-1339.

(90) Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999;283(5403):845-848.

(91) Peled A, Leykin I, Deckmann M, Shinitzky M. Evaluation of immune memory of human lymphocytes engrafted in SCID mice. Immunobiology 1999;201(1):145-150.

(92) Peled A, Grabovsky V, Habler L, Sandbank J, Arenzana-Seisdedos F, Petit I, et al. The chemokine SDF-1 stimulates integrin-mediated arrest of CD34+ cells on vascular endothelium under shear flow. J Clin Invest 1999;104(9):1199-1211.

(93) Peled A, Gonzalo JA, Lloyd C, Gutierrez-Ramos J-. The chemotactic cytokine Eotaxin acts as a granulocyte-macrophage colony-stimulating factor during lung inflammation. Blood 1998;91(6):1909-1916.

(94) Carramolino L, Lee BC, Zaballos A, Peled A, Barthelemy I, Shav-Tal Y, et al. Erratum: SA-1, a nuclear protein encoded by one member of a novel gene family: Molecular cloning and detection in hemopoietic organs (Gene (1997) 195 (151-159)). Gene 1998;206(2):283-285.

(95) Wolkowicz R, Peled A, Elkind NB, Rotter V. DNA-binding activity of wild-type p53 protein is mediated by the central part of the molecule and controlled by its C terminus. Cancer Detect Prev 1998;22(1):1-13.

(96) Daniel Y, Peled A, Huszar M, Shinitzky M. Dietary fish oil suppresses tumor growth and metastasis of Lewis lung carcinoma in mice. J Nutr Biochem 1997;8(11):619-622.

(97) Carramolino L, Lee BC, Zaballos A, Peled A, Barthelemy I, Shav-Tal Y, et al. SA-1, a nuclear protein encoded by one member of a novel gene family: Molecular cloning and detection in hemopoietic organs. Gene 1997;195(2):151-159.

(98) Haran-Ghera N, Krautghamer R, Lapidot T, Peled A, Dominguez MG, Stanley ER. Increased circulating colony-stimulating factor-1 (CSF-1) in SJL/J mice with radiation-induced acute myeloid leukemia (AML) is associated with autocrine regulation of AML cells by CSF-1. Blood 1997;89(7):2537-2545.

(99) Almog N, Li R, Peled A, Schwartz D, Wolkowicz R, Goldfinger N, et al. The murine C'-terminally alternatively spliced form of p53 induces attenuated apoptosis in myeloid cells. Mol Cell Biol 1997;17(2):713-722.

(100) Peled A, Shezen E, Schwartz D, Shav-Tal Y, Kushtai G, Lee B-, et al. Nuclear antigen expressed by proliferating cells. Hybridoma 1997;16(4):325-334.

(101) Schwartz D, Almog N, Peled A, Goldfinger N, Rotter V. Role of wild type p53 in the G2 phase: Regulation of the γ-irradiation-induced delay and DNA repair. Oncogene 1997;15(21):2597-2607.

(102) Aparicio J, Bilbao D, Aracil M, Peled A, Zipori D, Jochems G. The murine stromal cell line 14F1.1 secretes A putative novel growth factor for progenitor cells. Exp Hematol 1996;24(9):1118.

(103) Peled A, Schwartz D, Elkind NB, Wolkowicz R, Li R, Rotter V. The role of p53 in the induction of polyploidity of myelomonocytic leukemic M1/2 cells. Oncogene 1996;13(8):1677-1685.

(104) Peled A, Zipori D, Rotter V. Cooperation between p53-dependent and p53-independent apoptotic pathways in myeloid cells. Cancer Res 1996;56(9):2148-2156.

(105) Sternberg D, Peled A, Shezen E, Abramsky O, Jiang W, Bertolero F, et al. Control of stroma-dependent hematopoiesis by basic fibroblast growth factor: Stromal phenotypic plasticity and modified myelopoietic functions. Cytokines Mol Ther 1996;2(1):29-38.

(106) Lee B-, Shav-Tal Y, Peled A, Gothelf Y, Jiang W, Toledo J, et al. A hematopoietic organ-specific 49-kD nuclear antigen: Predominance in immature normal and tumor granulocytes and detection in hematopoietic precursor cells. Blood 1996;87(6):2283-2291.

(107) Peled A, Lee B-, Sternberg D, Toledo J, Aracil M, Zipori D. Interaction between leukemia cells and bone marrow stromal cellss: Stroma-supported growth vs. serum dependence and the roles of TGF-β and M-CSF. Exp Hematol 1996;24(6):728-737.

(108) Wolkowicz R, Peled A, Elkind NB, Rotter V. Augmented DNA-binding activity of p53 protein encoded by a carboxyl-terminal alternatively spliced mRNA is blocked by p53 protein encoded by the regularly spliced form. Proc Natl Acad Sci U S A 1995;92(15):6842-6846.

(109) Haran-Ghera N, Peled A, Wu L, Shortman K, Brightman BK, Fan H. The effects of passive antiviral immunotherapy in AKR mice: I. The susceptibility of AKR mice to spontaneous and induced t cell lymphomagenesis. Leukemia 1995;9(7):1199-1206.

(110) Peled A, Tzehoval E, Haran-Ghera N. Role of cytokines in termination of the B cell lymphoma dormant state in AKR mice. Leukemia 1995;9(6):1095-1101.

(111) Haran-Ghera N, Peled A, Canaani E, Caspi Y, Haimovich J, Shaft D, et al. The effects of passive anti-viral immunotherapy in AKR mice: II susceptibility to B cell lymphomagenesis. Leukemia 1995;9(11):1940-1947.

(112) Benayahu D, Peled A, Zipori D. Myeloblastic cell line expresses osteoclastic properties following coculture with marrow stromal adipocytes. J Cell Biochem 1994;56(3):374-384.

(113) Rosner A, Peled A, Haran-Ghera N, Canaani E. Analysis of Ly-1+ B-Cell Populations and IgH Rearrangements in “Normal” Spleens and in Lymphomas of AKR/J and AKR Fv-1b Mice. Cancer Res 1993;53(9):2147-2153.

(114) Haran-Ghera N, Peled A, Kay Brightman B, Fan H. Lymphomagenesis in AKRJ?v-lb Congenic Mice. Cancer Res 1993;53(14):3433-3438.

(115) Defresne M-, Borremans B, Verhofstede C, Peled A, Thiry A, Greimers R, et al. Mixed phenotype murine leukemias. Leukemia 1993;7(8):1253-1260.

(116) Resnitzky P, Goren T, Shaft D, Trakhtenbrot L, Peled A, Resnitzky D, et al. Absence of negative growth regulation in three new murine radiation-induced myeloid leukemia cell lines with deletion of chromosome 2. Leukemia 1992;6(12):1288-1295.

(117) Haran-Ghera N, Peled A, Krautghamer R, Resnitzky P. Initiation and promotion in radiation-induced myeloid leukemia. Leukemia 1992;6(7):689-695.

(118) Irlin Y, Peled A. Thy-1 antigen-mediated adhesion of mouse lymphoid cells to stromal cells of haemopoetic origin. Immunol Lett 1992;33(3):233-237.

(119) Haran-Ghera N, Peled A, Brightman BK, Fan H. Termination of the B cell lymphoma dormant state in thymectomized AKR mice. J Immunol 1992;148(9):2947-2952.

(120) Halevy O, Rodel J, Peled A, Oren M. Frequent p53 mutations in chemically induced murine fibrosarcoma. Oncogene 1991;6(9):1593-1600.

(121) Peled A, Kalai M, Toledo J, Zipori D. Stroma-cell dependent hematopoiesis. Semin Hematol 1991;28(2):132-137.

(122) Shaulsky G, Goldfinger N, Peled A, Rotter V. Involvement of wild-type p53 protein in the cell cycle requires nuclear localization. Cell Growth Differ 1991;2(12):661-667.

(123) Shaulsky G, Goldfinger N, Peled A, Rotter V. Involvement of wild-type p53 in pre-B-cell differentiation in vitro. Proc Natl Acad Sci U S A 1991;88(20):8982-8986.

(124) Haran-Ghera N, Peled A. II. Prevention of spontaneous AKR T cell lymphomagenesis by elimination of potential lymphoma cells with antibody to specific gp 71 determinants. Virology 1991;181(2):536-540.

(125) Peled A, Haran-Ghera N. I. Prevention of spontaneous AKR T cell lymphomagenesis by 24-666, a virus isolated from an AKR B cell lymphoma. Virology 1991;181(2):528-535.

(126) Haran-Ghera N, Peled A. Validity of the in vitro system as a correlate of the in vivo model of RadLV lymphomagenesis. Leukemia 1991;5(6):500-503.

(127) Peled A, Zipori D, Abramsky O, Ovadia H, Shezen E. Expression of α-smooth muscle actin in murine bone marrow stromal cells. Blood 1991;78(2):304-309.

(128) Gokhman I, Peled A, Haran-Ghera N. Characteristics of Potential Lymphoma-inducing Cells in Mice Sensitive or Resistant to Lymphomagenesis by Radiation Leukemia Virus Variants. Cancer Res 1990;50(9):2554-2561.

(129) Haran-Ghera N, Trakhtenbrot L, Resnitzky P, Peled A. Preleukemia in experimental leukemogenesis. Haematol Blood Transfus 1989;32:243-249.

(130) Peled A, Haran-Ghera N. Intervention in potential leukemic cell migration pathway affects leukemogenesis. Haematol Blood Transfus 1989;32:237-242.

(131) Peled A, Haran-Ghera N. Prevention of T-cell lymphoma in AKR/J mcie. Leukemia 1988;2(12 SUPPL.):125s-131s.

(132) Resnitzky P, Bustan A, Peled A, Marikovsky Y. Variations in surface charge distribution of leukemic and non-leukemic transformed cells. Leuk Res 1988;12(4):315-320.

(133) Haran-Ghera N, Peled A, Leef F, Hoffman AD, Levy JA. Enhanced AKR leukemogenesis by the dual tropic viruses. I. The time and site of origin of potential leukemic cells. Leukemia 1987;1(5):442-449.

(134) Peled A, Hoffman AD, Levy JA, Haran-Ghera N. Enhanced AKR leukemogenesis by the dual tropic viruses. II. Effect on cell-mediated immune responses. Leukemia 1987;1(5):450-456.

(135) Trakhtenbrot L, Peled A, Haran‐Ghera N. Cytogenetic studies on B‐cell leukemias of akr origin. Int J Cancer 1987;39(3):380-384.

(136) Peled A, Haran-Ghera N. High incidence of b cell lymphomas derived from thymectomized akr mice expressing TL.4 antigen. J Exp Med 1985;162(3):1081-1086.

(137) Katz E, Peled A, Haran-Ghera N. Changes of H-2 antigen expression on thymocytes during leukemia development by radiation leukemia virus. Leuk Res 1985;9(10):1219-1225.

(138) Peled A, Haran‐Ghera N. Age‐related expression of TL antigen in AKR/J mice. Int J Cancer 1984;34(1):121-126.

(139) Weinberger A, Peled A, Haran-Ghera N, Hazaz B, Joshua H, Pinkhas J. Infiltration of leukemic cells into muscles adjacent to joints of mice with leukemia. Isr J Med Sci 1982;18(10):1057-1059.

(140) Peled A, Perk K, Haran-Ghera N, Chirigos MA. The oncostatic effect of methyl-CCNU on various experimental lymphoreticular neoplasms. Leuk Res 1982;6(1):89-95.

(141) Lonai P, Katz E, Peled A, Haran-Ghera N. H-2I-linked control of immunological resistance to viral leukemogenesis as a response to preleukemic cells. Immunogenetics 1981;12(1):423-432.

(142) Haran-Ghera N, Krauthgamer R, Peled A. Malignant cell arrest in thymus and spleen of mice bearing transplanted tumors. J Immunol 1981;126(4):1241-1244.

(143) Geltner D, Peled A. Absorption of serum antinuclear antibodies. Clin Immunol Immunopathol 1979;13(3):237-245.

(144) Haran-Ghera N, Peled A. Induction of leukemia in mice by irradiation and radiation leukemia virus variants. Adv Cancer Res 1979;30(C):45-87.

(145) Peled A, Ben-Yaakov M, Brami S. The effect of lymphoreticular neoplasms on the age dependent increase of antinuclear antibodies. J Clin Lab Immunol 1979;2(3):255-260.

(146) Peled A, Haran-ghera N. Lack of transformation of murine thymocytes by thymic epithelium [24]. Nature 1978;274(5668):266-269.

(147) Peled A. Cellular immune response induced by the radiation leukemia virus (RadLV). Leuk Res 1977;1(4):333-343.

(148) Haran Ghera N, Ben Yaakov M, Peled A. Immunologic characteristics in relation to high and low leukemogenic activity of radiation leukemia virus variants. I. Cellular analysis of immunosuppression. J Immunol 1977;118(2):600-606.

(149) Haran Ghera N, Ben Yaakov M, Chazan R, Peled A. Pathways in thymus and bone marrow derived lymphatic leukemia in mice. Bibl Haematol 1975;no.40:133-141.

(150) Peled A, Berke G. Proceedings: Cell-mediated anti-leukemic cell immunity in C57BL/6 mice injected with the radiation leukemic virus. Isr J Med Sci 1975;11(12):1396.

(151) Peled A, Haran Ghera N. The cellular basis of immunosuppression caused by the radiation leukaemia virus. Immunology 1974;26(2):323-329.

(152) Haran-Ghera N, Peled A. Thymus and bone marrow derived lymphatic leukaemia in mice [7]. Nature 1973;241(5389):396-398.

(153) Haran-Ghera N, Ben-Yaakov M, Peled A, Bentwich Z. Immune status of sjl/j mice in relation to age and spontaneous tumor development. J Natl Cancer Inst 1973;50(5):1227-1235.

(154) Peled A, Haran-Ghera N. Immunological studies on the radiation leukaemia virus in C57BL mice. Nat New Biology 1971;232(34):244-245.

(155) Peled A, Haran‐Ghera N. Immunosuppression by the radiation leukemia virus and its relation to lymphatic leukemia development. Int J Cancer 1971;8(1):97-106.

(156) Haran-Ghera N, Peled A. The mechanism of radiation action in leukemogenesis. IV. Immune impairment as a coleukemogenic factor. Isr J Med Sci 1968;4(6):1181-1187.

(157) Haran-Ghera N, Peled A. The mechanism of radiation action in leukaemogenesis. Isolation of a leukaemogenic filtrable agent from tissues of irradiated and normal c57bl mice. Br J Cancer 1967;21(4):730.